Is Celestica The Best AI Stock to Buy Now?
Technology and hardware business Celestica (NYSE:CLS) has seen massive upward…
Sell
34
SHPMF Quote, Financials, Valuation and Earnings
Last price:
$1.46
Seasonality move
:
-2.15%
Day range:
$1.46 - $1.46
52-week range:
$1.46 - $1.56
Dividend yield:
3.93%
P/E ratio:
6.83x
P/S ratio:
0.14x
P/B ratio:
0.50x
Volume:
--
Avg. volume:
--
1-year change:
-6.55%
Market cap:
$5.4B
Revenue:
$39.4B
EPS (TTM):
$0.21
Analysts' Opinion
-
Consensus RatingNo consensus rating exists at this time due to lack of analyst coverage.
-
Price Target DownsideNo price target exists because of limited analyst coverage.
-
Price Target UpsideSimilarly, at this time, analysts have not provided a price target so downside risk can't be assessed accurately at this time.
Fair Value
-
According to the consensus of 0 analysts, Shanghai Pharmaceuticals Holding Co., Ltd. has -- downside to fair value with a price target of -- per share.
SHPMF vs. S&P 500
-
Over the past 5 trading days, Shanghai Pharmaceuticals Holding Co., Ltd. has underperformed the S&P 500 by -3.25% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Shanghai Pharmaceuticals Holding Co., Ltd. does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Shanghai Pharmaceuticals Holding Co., Ltd. has grown year-over-year revenues for 3 quarters straight. In the most recent quarter Shanghai Pharmaceuticals Holding Co., Ltd. reported revenues of $10.3B.
Earnings Growth
-
Shanghai Pharmaceuticals Holding Co., Ltd. has grown year-over-year earnings for 1 quarter straight. In the most recent quarter Shanghai Pharmaceuticals Holding Co., Ltd. reported earnings per share of $0.03.
Enterprise value:
10.7B
EV / Invested capital:
--
Price / LTM sales:
0.14x
EV / EBIT:
10.82x
EV / Revenue:
0.27x
PEG ratio (5yr expected):
0.27x
EV / Free cash flow:
17.38x
Price / Operating cash flow:
8.80x
Enterprise value / EBITDA:
7.57x
Gross Profit (TTM):
$4B
Return On Assets:
2.95%
Net Income Margin (TTM):
2.43%
Return On Equity:
7.87%
Return On Invested Capital:
4.56%
Operating Margin:
2%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-12-31 | 2024-12-31 | 2025-12-31 | 2024-12-31 | 2025-12-31 | |
| Income Statement | ||||||
| Revenue | $36.7B | $38.2B | $39.4B | $9.1B | $9.7B | |
| Gross Profit | $4.1B | $4B | $4B | $973.9M | $1.1B | |
| Operating Income | $1.1B | $1.2B | $988.1M | $222.3M | $245.8M | |
| EBITDA | $1.5B | $1.5B | $1.4B | $316.7M | $357.7M | |
| Diluted EPS | $0.15 | $0.17 | $0.21 | $0.02 | $0.02 | |
| Period Ending | 2021-12-31 | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2025-12-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $18.3B | $21.5B | $22.9B | $23.5B | $25.8B | |
| Total Assets | $25.6B | $28.5B | $29.9B | $30.4B | $33.5B | |
| Current Liabilities | $14.4B | $15.9B | $17.3B | $17.3B | $19.3B | |
| Total Liabilities | $16.3B | $17.2B | $18.5B | $18.9B | $20.5B | |
| Total Equity | $9.3B | $11.2B | $11.3B | $11.5B | $12.8B | |
| Total Debt | $1.5B | $1.6B | $1.5B | $1.5B | $1.2B | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-12-31 | 2024-12-31 | 2025-12-31 | 2024-12-31 | 2025-12-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | $858.6M | $997.8M | $943.2M | $474.1M | $563.6M | |
| Cash From Investing | -$454.9M | -$147.7M | -$654.1M | -$61.7M | -$492.4M | |
| Cash From Financing | $5.9M | -$242.9M | -$779.8M | -$260.6M | -$702.5M | |
| Free Cash Flow | $448.4M | $664.3M | $615.1M | $396.2M | $460.8M | |
SHPMF
Sector
Market Cap
$5.4B
$23.9M
Price % of 52-Week High
93.45%
47.44%
Dividend Yield
3.93%
0%
Shareholder Yield
3.43%
-1.9%
1-Year Price Total Return
-6.55%
-18.29%
Beta (5-Year)
0.601
0.513
Dividend yield:
3.93%
Annualized payout:
$0.06
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Sell
Level
$1.46
200-day SMA
Sell
Level
$1.51
Bollinger Bands (100)
Sell
Level
1.46 - 1.52
Chaikin Money Flow
Buy
Level
13.4K
20-day SMA
Sell
Level
$1.46
Relative Strength Index (RSI14)
Sell
Level
0.00
ADX Line
Sell
Level
99.99
Williams %R
Buy
Level
-100
50-day SMA
Sell
Level
$1.46
MACD (12, 26)
Sell
Level
0.00
25-day Aroon Oscillator
Sell
Level
0
On Balance Volume
Neutral
Level
206.2K
Financial Scores
Hold
Altman Z-Score
(Annual)
Level (1.9234)
Sell
CA Score
(Annual)
Level (-0.6289)
Sell
Beneish M-Score
(Annual)
Level (-2.1622)
Buy
Momentum Score
Level (6)
Buy
Ohlson Score
Level (-0.6207)
Buy
Piotroski F Score
(Annual)
Level (5)
Buy
Quality Ratio Score
Level (5)
Buy
Fundamental Score
Level (9)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Shanghai Pharmaceuticals Holding Co., Ltd. engages in the research and development, manufacture, distribution, and retail of pharmaceutical products. The company was founded on January 18, 1994 and is headquartered in Shanghai, China.
Stock Forecast FAQ
In the current month, SHPMF has received 0 Buy ratings 0 Hold ratings, and 0 Sell ratings. The SHPMF average analyst price target in the past 3 months is --.
-
Where Will Shanghai Pharmaceuticals Holding Co., Ltd. Stock Be In 1 Year?
According to analysts, the consensus estimate is that Shanghai Pharmaceuticals Holding Co., Ltd. share price will drop to -- per share over the next 12 months.
-
What Do Analysts Say About Shanghai Pharmaceuticals Holding Co., Ltd.?
Analysts are divided on their view about Shanghai Pharmaceuticals Holding Co., Ltd. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Shanghai Pharmaceuticals Holding Co., Ltd. is a Sell and believe this share price will rise from its current level to --.
-
What Is Shanghai Pharmaceuticals Holding Co., Ltd.'s Price Target?
The price target for Shanghai Pharmaceuticals Holding Co., Ltd. over the next 1-year time period is forecast to be -- according to 0 Wall Street analysts, 0 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is SHPMF A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Shanghai Pharmaceuticals Holding Co., Ltd. is a --. 0 of 0 analysts rate the stock a -- at this time.
-
How Can I Buy Shares Of SHPMF?
You can purchase shares of Shanghai Pharmaceuticals Holding Co., Ltd. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Shanghai Pharmaceuticals Holding Co., Ltd. shares.
-
What Is The Shanghai Pharmaceuticals Holding Co., Ltd. Share Price Today?
Shanghai Pharmaceuticals Holding Co., Ltd. was last trading at $1.46 per share. This represents the most recent stock quote for Shanghai Pharmaceuticals Holding Co., Ltd.. Yesterday, Shanghai Pharmaceuticals Holding Co., Ltd. closed at $1.46 per share.
-
How To Buy Shanghai Pharmaceuticals Holding Co., Ltd. Stock Online?
In order to purchase Shanghai Pharmaceuticals Holding Co., Ltd. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Related Companies
Get SHPMF Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
SHPMF
Sector
P/E ratio
6.83x
21.37x
PEG ratio
0.27x
-0.01x
P/B ratio
0.50x
1.72x
Price / LTM sales
0.14x
1.44x
Growth Metrics
SHPMF
Sector
Revenue growth
5.09%
3.44%
Earnings growth
-38.19%
14.97%
Revenue (5-year growth)
7.27%
6.27%
Earnings forecast
--
-$0.22
Profitability
SHPMF
Sector
Profitability FY 2025
$3.9B
$2.4M
Return on invested capital
4.56%
-33.43%
Return on assets
2.95%
-29.45%
Return on equity
7.87%
-40.29%
Earnings Date
Last Earnings Date
Oct
30
Next Earnings Date
Apr
27
Estimated Next Earnings Date
Jan
29
Balance Sheet
SHPMF
Sector
Total cash
$6.3B
$25.6M
Short term investments
$1.2B
$22.7M
Total assets
$33.5B
$70.4M
Long term debt
$1.3B
$2.4M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will AI Disrupt SaaS Software Stocks?
Since January 28th, software stocks in the United States have…
Why Is Meta Stock Going Higher?
Over the last five days, shares of Instagram and Facebook…
Stock Ideas
Sell
46
Is NVDA Stock a Buy?
Market Cap: $4.3T
P/E Ratio: 36x
Sell
50
Is AAPL Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 34x
Sell
40
Is GOOGL Stock a Buy?
Market Cap: $3.6T
P/E Ratio: 27x
Alerts
Buy
51
AAOI alert for Apr 3
Applied Optoelectronics, Inc. [AAOI] is up 20.3% over the past day.
Buy
59
SBAC alert for Apr 3
SBA Communications Corp. [SBAC] is up 18.96% over the past day.
Buy
55
VSAT alert for Apr 3
ViaSat, Inc. [VSAT] is up 18.73% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
